Clinical Trial Update: Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial of Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone for first-line treatment in multiple myeloma was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Grupo Cooperativo de Hemopatías Malignas | Conditions: Multiple Myeloma | Phase 3 | Status: WITHDRAWN